Pulse Biosciences

Company Overview

Pulse Biosciences, Inc. (Nasdaq: PLSE), headquartered in Miami, Florida, USA, is a bioelectric medicine company specializing in nanosecond pulsed field ablation (nsPFA) technology. Founded in 2014 as Electroblate, Inc. and renamed Pulse Biosciences in 2015, the company is led by co-chairman, CEO, and president Paul A. Laviolette. Key executives include Robert W. Duggan (co-chairman), Darrin R. Uecker (CTO), and Jon Skinner (CFO). As of September 2025, Pulse Biosciences employs 75 staff. 

Core Business and Technology

Pulse Biosciences develops and commercializes medical devices using its proprietary nsPFA technology, which applies ultrashort high-voltage electrical pulses to create nanoscale pores in cell membranes, leading to controlled cell apoptosis. Compared to conventional pulsed field ablation, nsPFA provides tissue selectivity and faster discharge times. The core product is the CellFX System, applied in:

• Dermatology: Treats benign skin lesions.

• Surgical: CellFX nsPFA Percutaneous Electrode for soft tissue ablation.

• Cardiology: CellFX nsPFA Cardiac Clamp and 360° Cardiac Catheter for atrial fibrillation (AF) treatment, plus a tunable, software-enabled CellFX console.

Market Position and Key Products

Pulse Biosciences is recognized for its breakthrough nsPFA technology. Its CellFX System is commercially available, and its nsPFA Cardiac Surgery System received FDA Breakthrough Device designation in 2024. The FDA also approved the Investigational Device Exemption (IDE) for the NANOCLAMP AF study in 2025, enabling the company to initiate a multi-site trial evaluating nsPFA efficacy in atrial fibrillation. The nsPFA cardiac clamp aims to replace conventional radiofrequency ablation devices, offering faster, safer, and more consistent ablation.

Financial Performance and R&D Investment

As of September 2025, Pulse Biosciences has a market capitalization of $1.01 billion and an enterprise value of $914.03 million. Its trailing 12-month revenue is not reported; net income attributable to common shareholders is -$68.03 million, with diluted EPS of -$1.08. Total cash is $106.35 million, debt-to-equity ratio is 7.89%, and levered free cash flow is -$21.69 million. A private placement in May 2023 raised $65 million to fund nsPFA technology development, including cardiac ablation catheters and clamps.

Research and Innovation

Pulse Biosciences continues to advance nsPFA technology, enabling ultrashort electrical pulses to ablate cardiac tissue without thermal damage. Its R&D focuses on dermatology, surgical, and cardiac applications. The upcoming NANOCLAMP AF trial in the U.S. will evaluate the safety and efficacy of the nsPFA Cardiac Surgery System for atrial fibrillation treatment.

Governance and Leadership

Leadership includes Paul A. Laviolette (co-chairman, CEO, president), Robert W. Duggan (co-chairman), Darrin R. Uecker (CTO), Jon Skinner (CFO), Kevin P. Danahy (CCO), Mitchell E. Levinson (CSO), and others. The board also includes Mahkam Zanganeh, Manmeet Singh Soni, Richard A. van den Broek, among others.

Contact Information

Address: 601 Brickell Key Drive, Suite 1080, Miami, Florida, USA